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QOL in PLE in the EU
To examine the impact of poly-
morphic light eruption (PLE) on 
quality of life, Ling et al. evalu-
ated the influence of season and 
latitude on 237 adult patients 
with PLE who attended hospi-
tal dermatology departments in 
Greece, France, the Netherlands, 
the United Kingdom, and 
Finland. The investigators were 
most interested in whether 
patients with PLE would judge 
their condition to affect them most in spring or summer, and at higher or lower lat-
itudes. A significant seasonal pattern in life-quality reduction was revealed, reflect-
ing the cycle in ambient UVR levels. The summer was seen as the season of maximal 
impairment, regardless of latitude. See page 1648 
Timing is Everything
Kostka and colleagues studied Leishmania 
major infections in IL-1 receptor type I (IL-
1RI) knockout mice to characterize the recep-
tor involved. They found that in C57BL/6 IL-
1RI–/– mice, the IL-1α-mediated protective 
effect was suppressed. Whereas prior studies 
showed that treatment of susceptible BALB/c 
mice with IL-1α during post-infection days 1–
3 induced T helper 1- mediated protection, 
this study demonstrated that prolonged treat-
ment (3 weeks) with IL-1α worsened disease 
outcome. In early phases of some low-dose 
L. major infections, therefore, IL-1 appears to 
facilitate immunity, but later IL-1RI signaling 
promotes T helper 2 expansion and abrogates that protection. See page 1582
Eczema: Sometimes Good for You
Gupta and co-workers, administering a contact sensi-
tizer to mice with alopecia areata (AA), tested whether 
the alterations of leukocyte traffic might contribute to 
the therapeutic efficacy of a chronic allergic eczema. 
They found that allergen treatment created an inflamma-
tory chemokine milieu that severely impeded dendritic-
cell migration from the skin toward the draining node. 
This allergic eczema-induced reduction in dendritic-cell 
migration and antigen transfer may be beneficial not only 
in AA, but also in other skin-related autoimmune diseas-
es. See page 1559
IL-20 in Psoriasis
Wang et al. examined 34 
psoriasis patients treated 
with the CD2-targeted 
agent alefacept. Some 
results regarding the newly 
discovered cytokine IL-20 
and its receptors (IL-20Rα 
and IL-20Rβ) contrasted 
with previous findings: 
immunoreactivity to IL-20 
protein was greater in lesional 
tissue and mainly localized 
to infiltrating CD68+/CD11c+ 
(myeloid-derived) dermal 
leukocytes; and the mRNA 
of IL-20Rα and IL-20Rβ was 
decreased in lesional versus 
normal skin. These findings 
suggest that CD2+ leukocytes 
may regulate IL-20 and thus 
that IL-20 may influence 
inflammation through IFN-like 
effects. Inhibition of IL-20 and 
its receptors may represent a 
potential therapeutic target. 
See page 1590 
Enzastaurin-Induced 
Apoptosis in CTCL
Protein kinase C (PKC) is part 
of a family of serine–threonine 
protein kinases involved in 
signal transduction pathways 
that regulate growth factor 
response, proliferation, and 
apoptosis. T lymphocytes 
express a number of PKC 
isoforms. Querfeld and 
colleagues at Northwestern 
University have shown 
that the PKC β inhibitor 
enzastaurin inhibits cell growth 
and induces apoptosis via 
inhibition of the AKT signaling 
pathway in the cutaneous 
T-cell lymphoma (CTCL) cell 
lines HuT-78 and HH. Further 
in vivo studies can address 
enzastaurin’s therapeutic 
efficacy in CTCL patients. See 
page 1641
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